ISA Shun-Ichi 伊佐俊一

… Alternative Names

伊佐俊一イサシユンイチ

Less

Researcher Number	60421913
Affiliation (Current)	2025: 独立行政法人国立病院機構近畿中央呼吸器センター, その他部局等, 呼吸不全研究部長
Affiliation (based on the past Project Information) *help	2014: 独立行政法人国立病院機構, 近畿中央胸部疾患センター臨床研究センター, 研究員
Review Section/Research Field	Except Principal Investigator Clinical oncology
Keywords	Except Principal Investigator サイトケラチン / 化学療法 / FDG-PET / 薬物動態 / 薬力学 / 分子標的治療 / 癌性胸膜炎 / 非小細胞肺癌

Nobel pharmacodynamics evaluation of molecular targeting agents: PHarmacokinetic/PHarmacodynamic Assessment on Malignant Effusions (PHAME)
- Principal Investigator
  
  KUBO Akihito
- Project Period (FY)
  2011 – 2014
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Clinical oncology
- Research Institution
  Aichi Medical University

All 2015 2014 2013 2011 Other

All Journal Article Presentation

[Journal Article] The role of smoking status on the progression-free survival of non-small-cell lung cancer patients harboring activating epidermal growth factor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor: a meta-analysis of prospective randomized trials.2015
- Author(s)
  Hasegawa Y, Ando M, Maemondo M, Yamamoto S, Isa S, Saka H, Kubo A, Kawaguchi T, Takada M, Rosell R, Kurata T, Ou SH.
- Journal Title
  
  The Oncologist
  
  Volume: 20 Issue: 3 Pages: 1-9
- DOI
  10.1634/theoncologist.2014-0285
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23501314, KAKENHI-PROJECT-15K09237, KAKENHI-PROJECT-25460896
[Journal Article] Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small-cell lung cancer patients with an EGFR-activating mutation using picodroplet digital PCR.2015
- Author(s)
  Watanabe M, Kawaguchi T, Isa S-I, Ando M, Tamiya A, Kubo A, Saka H, Takeo S, Adachi H, Tagawa T, Kakegawa S, Yamashita M, Kataoka K, Ichinose Y, Takeuchi Y, Sakamoto K, Matsumura A, Koh Y.
- Journal Title
  
  Clin Cancer Res
  
  Volume: in press Issue: 15 Pages: 3552-3560
- DOI
  10.1158/1078-0432.ccr-14-2151
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23501314, KAKENHI-PROJECT-25460896
[Journal Article] Long-term complete response in a patient with disseminated pulmonary pleomorphic carcinoma induced by cisplatin and gemcitabine.2014
- Author(s)
  Tamiya A, Asami K, Shimizu S, Matusmura A, Isa S-I, Okishio K, Kitaichi M, Atagi S, Takada M, Kawaguchi T, Kubo A
- Journal Title
  
  Internal Medicine (in press)
  
  Volume: na
- NAID
  130004713245
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23501314
[Journal Article] Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small cell lung cancer: Docetaxel and Erlotinib Lung cancer TriAl (DELTA).2014
- Author(s)
  Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H, Ibata H, Kozuki T, Endo T, Tamura A, Kamimura M, Sakamoto K, Yoshimi M, Soejima Y, Tomizawa Y, Isa S, Takada M, Saka H, Kubo A.
- Journal Title
  
  J Clin Oncol
  
  Volume: 32 Issue: 18 Pages: 1902-8
- DOI
  10.1200/jco.2013.52.4694
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23501314, KAKENHI-PROJECT-25460896
[Journal Article] Human papilloma virus in non-small cell lung cancer in never smokers: A systematic review of the literature.2014
- Author(s)
  Hasegawa Y, Ando M, Kubo A, Isa SI, Yamamoto S, Tsujino K, Kurata T, Ou SH, Takada M, Kawaguchi T
- Journal Title
  
  Lung Cancer
  
  Volume: 8 Issue: 1 Pages: 8-13
- DOI
  10.1016/j.lungcan.2013.10.002
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23501314, KAKENHI-PROJECT-25460896
[Journal Article] Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small cell lung cancer: Docetaxel and Erlotinib Lung cancer TriAl (DELTA).2014
- Author(s)
  Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H, Ibata H, Kozuki T, Endo T, Tamura A, Kamimura M, Sakamoto K, Yoshimi M, Soejima Y, Tomizawa Y, Isa S, Takada M, Saka H, Kubo A
- Journal Title
  
  J Clin Oncol (in press)
  
  Volume: na
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23501314
[Journal Article] Long-term Complete Response in a Patient with Disseminated Pulmonary Pleomorphic Carcinoma Induced by Cisplatin and Gemcitabine2014
- Author(s)
  Tamiya A, Asami K, Shimizu S, Matusmura A, Isa S-I, Okishio K, Kitaichi M, Atagi S, Takada M, Kawaguchi T, Kubo A.
- Journal Title
  
  Intern. Med.
  
  Volume: 53 Issue: 22 Pages: 2625-2628
- DOI
  10.2169/internalmedicine.53.2637
- NAID
  130004713245
- ISSN
  0918-2918, 1349-7235
- Language
  English
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-23501314
[Journal Article] Rationale and Design of the Japan Molecular Epidemiology for Lung Cancer Study2013
- Author(s)
  Kawaguchi T, Ando M, Ito N, Isa SI, Tamiya A, Shimizu S, Saka H, Kubo A, Koh Y, Matsumura A
- Journal Title
  
  Clin Lung Cancer
  
  Volume: 14 Issue: 5 Pages: 596-600
- DOI
  10.1016/j.cllc.2013.03.001
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23501314, KAKENHI-PROJECT-24501363, KAKENHI-PROJECT-25460896
[Journal Article] Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non-Small-Cell Lung Cancer?: A Pooled Analysis of the Literature.2013
- Author(s)
  Tsujino K, Kurata T, Yamamoto S, Kawaguchi T, Kubo A, Isa S, Hasegawa Y, Ou SH, Takada M, Ando M
- Journal Title
  
  J Thorac Oncol
  
  Volume: 8 Issue: 9 Pages: 1181-9
- DOI
  10.1097/jto.0b013e3182988348
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23501314, KAKENHI-PROJECT-25460896
[Presentation] Randomized phase III trial of erlotinib (E) versus (v) docetaxel (D) as second or third line therapy in patients with advanced non-small cell lung cancer (NSCLC) who have wild type or mutant epidermal growth factor receptor (EGFR): Docetaxel and Erlotinib Lung cancer TriAl (DELTA).2013
- Author(s)
  Okano Y, Ando M, Asami K, Fukuda M, Nakagawa H, Ibata H, Kozuki T, Endo T, Tamura A, Kamimura M, Sakamoto K, Yoshimi M, Soejima Y, Tomizawa Y, Isa S, Takada M, Saka H, Kubo A, Kawaguchi T.
- Organizer
  Annual Meeting of the American Society of Clinical Oncology
- Place of Presentation
  Chicago, IL, USA
- Data Source
  KAKENHI-PROJECT-23501314
[Presentation] 非小細胞肺癌(NSCLC)の癌性胸膜炎(MPE)におけるゲフィチニブの薬力学・薬物動態・臨床第II相試験2011
- Author(s)
  久保昭仁、洪　泰浩、堀　隆、伊佐俊一、福岡順也、川口知哉、安藤昌彦、岡本　勇、北市正則、安宅信二、河原正明、楠　洋子、山口悦郎、中川和彦、高田　實
- Organizer
  第51回日本呼吸器学会学術講演会
- Place of Presentation
  東京
- Data Source
  KAKENHI-PROJECT-23501314
[Presentation] Updated overall survival (OS) results of randomized phase III trial of erlotinib (E) versus (v) docetaxel (D) as second or third line therapy in patients with advanced non-small cell lung cancer (NSCLC): Docetaxel and Erlotinib Lung cancer TriAl (DELTA).
- Author(s)
  Ibata H, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H, Kozuki T, Endo T, Tamura A, Kamimura M, Sakamoto K, Yoshimi M, Soejima Y, Tomizawa Y, Isa S, Takada M, Saka H, Kubo A, Kawaguchi T.
- Organizer
  Annual Meeting of the American Society of Clinical Oncology
- Place of Presentation
  Chicago, IL, USA.
- Year and Date
  2014-05-30 – 2014-06-03
- Data Source
  KAKENHI-PROJECT-23501314
[Presentation] The role of smoking status on the progression-free survival of non-small-cell lung cancer patients harboring activating epidermal growth factor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor: a meta-analysis of prospective randomized trials.
- Author(s)
  Hasegawa Y, Ando M, Maemondo M, Yamamoto S, Isa S, Saka H, Kubo A, Kawaguchi T, Takada M, Kurata T, Ou SH.
- Organizer
  Annual Meeting of the American Society of Clinical Oncology
- Place of Presentation
  Chicago, IL, USA.
- Year and Date
  2014-05-30 – 2014-06-03
- Data Source
  KAKENHI-PROJECT-23501314

1. KUBO Akihito (60416245)

# of Collaborated Projects: 1 results

# of Collaborated Products: 12 results
2. KOU Yasuhiro (80426519)

# of Collaborated Projects: 1 results

# of Collaborated Products: 3 results
3. FUKUOKA Junya (00324575)

# of Collaborated Projects: 1 results

# of Collaborated Products: 1 results
4. TAKADA Minoru (20373516)

# of Collaborated Projects: 1 results

# of Collaborated Products: 10 results
5. KAWAGUCHI Tomoya (70254422)

# of Collaborated Projects: 1 results

# of Collaborated Products: 12 results

ISA Shun-Ichi 伊佐 俊一

伊佐 俊一 イサ シユンイチ

Research Projects

Research Products

Co-Researchers

Nobel pharmacodynamics evaluation of molecular targeting agents: PHarmacokinetic/PHarmacodynamic Assessment on Malignant Effusions (PHAME)

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Journal Article] The role of smoking status on the progression-free survival of non-small-cell lung cancer patients harboring activating epidermal growth factor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor: a meta-analysis of prospective randomized trials.2015

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small-cell lung cancer patients with an EGFR-activating mutation using picodroplet digital PCR.2015

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Long-term complete response in a patient with disseminated pulmonary pleomorphic carcinoma induced by cisplatin and gemcitabine.2014

Author(s)

Journal Title

NAID

Data Source

[Journal Article] Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small cell lung cancer: Docetaxel and Erlotinib Lung cancer TriAl (DELTA).2014

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Human papilloma virus in non-small cell lung cancer in never smokers: A systematic review of the literature.2014

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small cell lung cancer: Docetaxel and Erlotinib Lung cancer TriAl (DELTA).2014

Author(s)

Journal Title

Data Source

[Journal Article] Long-term Complete Response in a Patient with Disseminated Pulmonary Pleomorphic Carcinoma Induced by Cisplatin and Gemcitabine2014

Author(s)

Journal Title

DOI

NAID

ISSN

Language

Data Source

[Journal Article] Rationale and Design of the Japan Molecular Epidemiology for Lung Cancer Study2013

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non-Small-Cell Lung Cancer?: A Pooled Analysis of the Literature.2013

Author(s)

Journal Title

DOI

Data Source

Author(s)

Organizer

Place of Presentation

Data Source

[Presentation] 非小細胞肺癌(NSCLC)の癌性胸膜炎(MPE)におけるゲフィチニブの薬力学・薬物動態・臨床第II相試験2011

Author(s)

Organizer

Place of Presentation

Data Source

[Presentation] Updated overall survival (OS) results of randomized phase III trial of erlotinib (E) versus (v) docetaxel (D) as second or third line therapy in patients with advanced non-small cell lung cancer (NSCLC): Docetaxel and Erlotinib Lung cancer TriAl (DELTA).

Author(s)

Organizer

Place of Presentation

Year and Date

Data Source

[Presentation] The role of smoking status on the progression-free survival of non-small-cell lung cancer patients harboring activating epidermal growth factor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor: a meta-analysis of prospective randomized trials.

Author(s)

Organizer

Place of Presentation

Year and Date

Data Source

ISA Shun-Ichi 伊佐俊一

伊佐俊一イサシユンイチ